Correction to: Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT.

An amendment to this paper has been published and can be accessed via the original article.

Correction to: Arthritis Res Ther (2019)21:272

https://doi.org/10.1186/s13075-019-2037-1

Following publication of the original article [1], the authors reported an error in some of the data values in Fig. 2a. The correct Fig. 2a can be seen below.

Fig. 2

Percentage of patients reporting improvements ≥ MCID at week 12. a Patient’s Global Assessment of Disease Activity (PtGA), pain, Health Assessment Questionnaire-Disability Index (HAQ-DI), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), morning (AM) joint stiffness duration, AM stiffness severity, Work Instability Scale for RA (RA-WIS), and Short Form 36 Health Survey (SF-36)